From precision genomics and synthetic biology to AI-driven drug discovery, Aevum Zenth Biotechnology accelerates the path from lab bench to clinical breakthrough.
Our multidisciplinary teams tackle complex biological systems with computational precision, advanced manufacturing, and ethical innovation.
Next-generation base editing, epigenetic modulation, and viral vector delivery systems for hereditary and acquired diseases.
12 Active ProgramsEngineered microbial consortia, cell-free protein synthesis, and bio-computational circuits for sustainable therapeutics.
GMP ScaledAI/ML molecular docking, protein folding prediction, and multi-omics integration platforms accelerating target identification.
Proprietary StackCell & gene therapies (CAR-T, mRNA platforms), oligonucleotide drugs, and targeted protein degradation payloads.
Phase II ReadyContinuous bioprocessing, single-use bioreactors, and automated purification pipelines meeting FDA/EMA cGMP standards.
3 Global SitesLiquid biopsy panels, single-cell sequencing arrays, and real-time biomarker monitoring for companion diagnostic pairing.
CLIA CertifiedStrategic allocation across early-stage discovery and late-stage clinical validation ensures sustainable innovation.
| Program Code | Target / Indication | Modality | Stage | Expected Readout |
|---|---|---|---|---|
| AZB-774 | BRCA1/2 Deficient Solid Tumors | Synthetic Lethality mRNA | Phase II | Q3 2026 |
| AZB-902 | Rare Metabolic Disorders | AAV Gene Replacement | Phase I | Q1 2027 |
| AZB-318 | Autoimmune Neuropathy | Selective Kinase Degrader | Preclinical | \nIND Filing Q4 2026 |
| AZB-550 | Hematologic Malignancies | Next-Gen CAR-T | Phase III | Surveillance Ongoing |
| AZB-119 | Infectious Disease Panel | Antibody-MAB Conjugate | Phase I/II | Q2 2027 |
Our integrated R&D campuses combine wet-lab discovery, computational modeling, and automated GMP manufacturing under one roof, reducing development timelines by up to 40%.
Strategic alliances with leading academic institutions, biopharma leaders, and regulatory bodies to de-risk development and scale therapeutics.
Joint research labs with MIT, ETH Zurich, and Imperial College for foundational biology breakthroughs.
Global trial sites across 28 countries enabling rapid patient recruitment and real-world evidence generation.
Licensing and co-promotion frameworks with Tier-1 biologics companies for late-stage scale-up.
Whether you're a clinical investigator, biotech startup, or potential collaborator, our science team is ready to explore synergies.